News
News from ESHRE 2026
Prolistem successfully participated in the ESHRE 2026 Annual Meeting, where our team met with fertility specialists, researchers, and industry partners from around the world to discuss the latest developments in reproductive medicine.
During the meeting, we had the opportunity to present and discuss our scientific approach for men with non-obstructive azoospermia (NOA), exchange clinical experience, and establish new collaborations with leading IVF centers and healthcare professionals.
We would like to thank everyone who visited the Prolistem booth and took the time to meet with our team. Your interest, valuable discussions, and continued support reinforce our commitment to advancing evidence-based solutions for male infertility.
We look forward to continuing these collaborations and to seeing you at ESHRE 2027 in Stockholm.
Clinical Study Presented at ESHRE…
Clinical Study Presented at ESHRE 2026 Demonstrates Encouraging Outcomes with Prolistem in…
Male Infertility Symposium – Landmark…
The Jordanian Society for Fertility and Genetics recently hosted a scientific symposium…
Prolistem® at the ESHRE 41th…
We are proud to have participated in the 41st Annual ESHRE Conference…
NEW STUDY: ENHANCING MICROTESE SUCCESS,…
OBJECTIVE To evaluate the efficacy of Prolistem, a novel supplement, in enhancing…
Prolistem® at the ESHRE 40th…
We are honored to participate in the highly anticipated ESHRE 2024 Conference,…
Prolistem® at the ASRM– Denver…
We are honored to participate in the prestigious ASRM 2024 Conference in…
Prolistem® Joins the ASRM 2024…
Prolistem® Joins the ASRM 2024 Conference in Denver We are thrilled to…
Prolistem® Clinical Approved by the…
The Prolistem treatment has emerged as a breakthrough for men grappling with…
Prolistem® approved by JFDA
We are thrilled to announce that Prolistem®, developed by Medhija LLC, has…









